Viridian Therapeutics earnings were -$360.6M for the trailing 12 months ending Mar 31, 2026, with N/A growth year over year. The latest VRDN earnings report on Mar 31, 2026 announced Q1 2026 earnings of -$104.9M, down 12.8% from last quarter. For the last reported fiscal year 2025 ending Dec 31, 2025, VRDN reported annual earnings of -$342.6M, with 26.9% growth.
Viridian Therapeutics Earnings Reports & History FAQ
What were Viridian Therapeutics's earnings last quarter?
Viridian Therapeutics (NASDAQ: VRDN) reported Q1 2026 earnings per share (EPS) of -$0.90, up 3.45% year over year. Total VRDN earnings for the quarter were -$104.90 million. In the same quarter last year, Viridian Therapeutics's earnings per share (EPS) was -$0.87.
Is Viridian Therapeutics profitable or losing money?
As of the last Viridian Therapeutics earnings report, Viridian Therapeutics is currently losing money. Viridian Therapeutics's net profit (also called net income) for the twelve months ending Mar 31, 2026 was -$360.59 million, a 16.95% increase year over year.
What was VRDN's earnings growth in the past year?
As of Viridian Therapeutics's earnings date in Q2 2026, Viridian Therapeutics's earnings has grown year over year. VRDN earnings in the past year totalled -$360.59 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.